Elranatamab
Pfizer
['mmsm']
aa7: cont - prior bdt: 68%adc/41%car-t/ both adc &amp; car-t 9%
- bdt refractory: 62%
- triple class rrmm: 97%
- penta class rrmm: 55% #mmsm #myeloma #usmirc #asco23 #medtwitter 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter